Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that data from two iclaprim clinical studies have been accepted for presentation at the Infectious Disease Week 2015 (ID Week) conference in San Diego, California which runs from the 7 th to the 11 th of October 2015. Iclaprim is a novel antibiotic, targeting the bacterial dihydrofolate reductase enzyme, currently beginning two Phase III studies to treat acute bacterial skin and skin structure infections (ABSSSI).
The two posters:
(1) “Cessation of Spread of Lesion and Absence of Fever at 72 hours in Complicated Skin and Skin Structure Infection (cSSSI): Reanalysis of the Combined ASSIST Phase III Studies Comparing Iclaprim (ICL) and Linezolid (LZD).” Skin and skin structure infections (SSSI) are a challenging medical problem associated with high direct and indirect costs to both medical systems and society. Infection due to bacteria with resistance to previously effective antimicrobials such as MRSA are highly prevalent and have led to high rates of complications and hospitalization. This poster presents data on the reanalysis of the Phase III cSSSI studies comparing iclaprim to linezolid, a standard of care treatment of SSSI, using endpoints similar to the FDA’s recently changed guidelines for ABSSSI trials.
(2) “Randomized, Double-Blind, Multicenter Phase II Study to Evaluate Efficacy and Safety of Intravenous Iclaprim (ICL) versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia Suspected or Confirmed Caused by Gram-positive Pathogens.”
Hospital-acquired bacterial pneumonia (HABP), including ventilator-associated pneumonia (VAP), and healthcare-associated pneumonia (HCAP) are commonly caused by Staphylococcus aureus, including MRSA. Despite the available antibiotics to treat HABP, VAP, and HCAP, clinical failures occur due to infections caused by antibiotic-resistant bacteria, intolerance to drugs due to adverse events, or reduced penetration of drugs at the site of infection. It is estimated that an average of 30% (ranging from 14%-50%) of HABP cases will result in death directly attributable to this infection. This poster presents data on outcomes related to treatment with iclaprim compared to vancomycin, a standard of care treatment of HABP, VAP and HCAP.
The posters will be presented on 9 October 2015 at 12:30 PM - 2:00 PM at the San Diego Convention Center Poster Hall.
Enquiries
Motif Bio plc
Graham Lumsden (Chief Executive Officer)
David Huang (Chief Medical Officer)
www.motifbio.com
info@motifbio.com
MC Services AG (TRADE PR)
Raimund Gabriel
Shaun Brown
+49 (0) 89 210 2280
+44 (0) 207 148 5998
Plumtree Capital Limited (FINANCIAL ADVISOR)
+44 (0) 207 183 2493
Stephen Austin
Yellow Jersey PR Limited (FINANCIAL PR)
Charles Goodwin
Dominic Barretto
+44 (0) 7747 788 221
Notes to Editors:
Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.
Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus ) and MDRSP (multi-drug resistant Streptococcus pneumoniae ) that have become prevalent in patients in both the community and hospital settings.
The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.
Help employers find you! Check out all the jobs and post your resume.
